The MMR rate was 66% at 6 months and 85% at 12 months ... early-stage, chronic-phase Ph+ CML patients” comment the researchers. The investigators also noted that the magnitude and rapidity ...

Chronic myeloid leukemia (CML) is a hematologic neoplasm with a progressive, ultimately terminal, disease course. In most cases, CML arises owing to the aberrant formation of a chimeric gene for a ...

CCyR: Complete cytogenetic remission; CML: Chronic myeloid leukemia ... Imatinib standard versus high dose imatinib trial; MMR: Major molecular remission; NA: Not available; SD: Standard dose ...

These data showed that, in patients with CP-CML who were resistant/intolerant to one prior line of TKIs, olverembatinib demonstrated a complete cytogenetic response (CCyR) rate of 74.1%, a major ...

In ASC4FIRST, 68% of patients treated with Scemblix had a major molecular response (MMR) after 48 weeks ... dramatic impact that TKIs have had in CML – including a tripling in the five-year ...

While many have been backing Tern more for that drug, the CML market “is long-established ... our optimism surrounding longer-term MMR data,” which is expected in the fourth quarter of ...

The Scemblix MMR rate was 15.1% higher vs ... of efficacy and tolerability profiles to help newly diagnosed adult CML patients achieve and maintain treatment goals,” said Jorge Cortes, M.D ...